<style face="normal" font="default" size="100%">780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors</style>

Drupal-HighWire